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Molecular Medicine
S-Endoglin Expression Is Induced in Senescent Endothelial
Cells and Contributes to Vascular Pathology
Francisco J. Blanco, María T. Grande, Carmen Langa, Barbara Oujo, Soraya Velasco,
Alicia Rodriguez-Barbero, Eduardo Perez-Gomez, Miguel Quintanilla,
Jose M. Lo´pez-Novoa, Carmelo Bernabeu
Abstract—Senescence of endothelial cells (ECs) may contribute to age-associated cardiovascular diseases, including
atherosclerosis and hypertension. The functional and gene expression changes associated with cellular senescence are
poorly understood. Here, we have analyzed the expression, during EC senescence, of 2 different isoforms (L, long; S,
short) of endoglin, an auxiliary transforming growth factor (TGF)- receptor involved in vascular remodeling and
angiogenesis. As evidenced by RT-PCR, the S/L ratio of endoglin isoforms was increased during senescence of human
ECs in vitro, as well as during aging of mice in vascularized tissues. Next, the effect of S-endoglin protein on the TGF-
receptor complex was studied. As revealed by coimmunoprecipitation assays, S-endoglin was able to interact with both
TGF- type I receptors, ALK5 and ALK1, although the interaction with ALK5 was stronger than with ALK1.
S-endoglin conferred a lower proliferation rate to ECs and behaved differently from L-endoglin in relation to
TGF-–responsive reporters with ALK1 or ALK5 specificities, mimicking the behavior of the endothelial senescence
markers Id1 and plasminogen activator inhibitor-1. In situ hybridization studies demonstrated the expression of
S-endoglin in the endothelium from human arteries. Transgenic mice overexpressing S-endoglin in ECs showed
hypertension, decreased hypertensive response to NO inhibition, decreased vasodilatory response to TGF-1 adminis-
tration, and decreased endothelial nitric oxide synthase expression in lungs and kidneys, supporting the involvement of
S-endoglin in the NO-dependent vascular homeostasis. Taken together, these results suggest that S-endoglin is induced
during endothelial senescence and may contribute to age-dependent vascular pathology. (Circ Res. 2008;103:1383-1392.)
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Cardiovascular repair mechanisms become progressivelyimpaired with age, and advanced age is itself a
significant risk factor for cardiovascular disease.1 Defects
in age-associated remodeling of the vascular wall are, in
part, attributable to the declining of endothelial function.2,3
Thus, vascular processes such as angiogenesis, nutrient
trafficking, vascular repair, and homeostasis are impaired
because of attenuation of endothelial cell (EC) prolifera-
tion, migration, or dilator responses. EC proliferation
diminishes with age, entering in an irreversible senescent
state.4 Senescent cells undergo growth arrest in the G1
phase and a change in morphology and metabolism. Some
of the senescence-associated changes include cellular en-
largement, altered response to growth factors such as
transforming growth factor (TGF)-1, and expression of
senescence-associated -galactosidase (SA--gal).5 Also,
alterations in the expression and/or activity of the endo-
thelial nitric oxide synthase (eNOS) are critical for the
attenuation of the endothelium-dependent dilatory re-
sponses with age.6,7 Unfortunately, most of the functional
and gene expression changes associated with EC senes-
cence remain largely unknown.2,4
TGF- is a family of multifunctional cytokines that regu-
late EC growth, differentiation, migration, senescence, extra-
cellular matrix production, and angiogenesis.8 These func-
tions are mediated through binding to a TGF-–specific
membrane receptor complex in ECs that contains 3 types of
receptors: types I (TRI) and II (TRII), with cytoplasmic
Ser/Thr-kinase activity8; and an auxiliary receptor named
endoglin.9 Two different TRIs, named ALK5 and ALK1,
have been shown to balance TGF- signaling by regulating
opposite functions in ECs.8 Activation of the receptor com-
plex triggers the phosphorylation by TRI of the Smad
family of proteins, which translocate to the nucleus to
regulate gene expression. The activated TRI determines the
specificity of the downstream signaling. Thus, ALK5 phos-
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phorylates Smad2/Smad3, whereas ALK1 activates
Smad1/Smad5.8
Endoglin is a 180-kDa homodimer predominantly ex-
pressed in ECs that plays an important role in angiogenesis,
vascular remodeling, and vascular pathology.9 Mutations in
endoglin and ALK1 genes are responsible for an autosomal
dominant vascular dysplasia termed hereditary hemorrhagic
telangiectasia, characterized by recurrent hemorrhages and
cerebral, hepatic, and pulmonary arteriovenous malforma-
tions.8 The in vivo expression of 2 different alternatively
spliced isoforms, long (L)-endoglin and short (S)-endoglin,
has been demonstrated in human and mouse tissues.10–12
L-endoglin, the predominant isoform in ECs, directly inter-
acts with ALK1, ALK5, and TRII13,14 and modulates EC
Figure 1. Effect of endothelial senescence on S-endoglin expression. A, Analysis of SA--gal activity in primary culture of HUVECs.
Cells were seeded onto gelatin-coated plates, and passages were performed when cells achieved 90% confluence. Blue cytoplasmic
staining is indicative of SA--gal activity. Representative phase contrast microscopy fields from young (second passage) and senescent
(13th passage) cells are included (left). Cells positive for SA--gal were counted from 4 random fields, and the percentage of senescent
cells was represented as the meansSEM (right). B, Schematic representation of alternative splicing in the human endoglin gene
(ENG). A 135-bp intron between exons E13 and E14 is retained, and a premature stop codon (†) arrests translation, giving rise to
S-endoglin. L-endoglin is synthesized when the same 135-bp intron is spliced and translation stops in E14 (‡). Endoglin primers that
simultaneously amplify both isoforms are indicated with red arrows. Amino acid sequences from S- and L-endoglin cytoplasmic tails
are shown. Sequences that differ between L and S isoforms are in blue. C through E, RT-PCR. C, Total RNA was isolated from
HUVECs and submitted to semiquantitative RT-PCR using specific primers for S- and L-endoglin, TRII, and GAPDH as an internal
control. D, Total endoglin and TRII levels. E, S-endoglin/L-endoglin ratio. F and G, Effect of aging on S-endoglin expression. F, Sche-
matic representation of alternative splicing in mouse endoglin gene (eng). Primers that specifically amplify S-endoglin are indicated with
red arrows. Cytoplasmic amino acid sequences that differ between L and S isoforms are in blue. G, Total RNA was isolated from lungs
of mice of different ages and submitted to quantitative RT-PCR. The amount of S-endoglin amplificate (2Ct) was normalized to the
endogenous 18S RNA. Each circle represents the mean of triplicates with an SD of 2% (nnumber of animals).
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responses to TGF-.13,15–17 Whereas L-endoglin represses the
TGF-/ALK5/Smad3 pathway involved in plasminogen ac-
tivator inhibitor (PAI)-1 expression,18,19 it activates that of
TGF-/ALK5/Smad2 to enhance eNOS expression20,21 and
triggers the TGF-/ALK1/Smad1 route to increase Id1 ex-
pression.13,15 Although, the role of S-endoglin in TGF-
signaling has been recently addressed in keratinocytes12 and
myoblasts,22 little is known about the expression and function
of S-endoglin in ECs. Here, we have analyzed the enhanced
expression of S-endoglin during EC senescence and the
functions affected by this isoform.
Materials and Methods
Cell culture13,19,23; senescence-associated -gal staining5; semiquan-
titative and quantitative RT-PCR11,24; in situ hybridization and
expression vectors12,14; reporter assays13; transgenic mice expressing
human S-endoglin in ECs (S-Eng mice)25; transfections, immu-
noprecipitation, and Western blot analyses13,20,26; urinary nitrite
measurements20; and radiotelemetry monitoring of blood pres-
sure27 are described in the expanded Materials and Methods
section in the online data supplement, available online at http://
circres.ahajournals.org.
Results
S-Endoglin Expression Increases in Senescent ECs
Human umbilical vein endothelial cell (HUVEC) primary
cultures showed increased senescence morphology along the
number of passages, as evidenced by the blue SA--gal
activity staining of their cytoplasm (Figure 1A). The size of
SA--gal–positive cells was significantly larger than that of
SA--gal negative cells, as expected for senescent cells
(Figure I in the online data supplement). At the 14th passage,
cells stopped proliferating, in agreement with the high per-
centage of senescent cells. At each passage, total RNA from
HUVECs was isolated and subjected to RT-PCR using
specific primers to detect TRII and endoglin transcripts
(Figure 1B). Along the different passages, no significant
differences were obtained in the expression levels of total
endoglin or TRII (Figure 1C and 1D). Interestingly,
S-endoglin began to be expressed at the 12th passage and
displayed the highest expression level at the 14th passage
(Figure 1C and 1E), sharing expression with its longer
counterpart in senescent cells. Next, the expression of mouse
S-endoglin during endothelial senescence in vivo was as-
sessed. As determined by quantitative RT-PCR using specific
primers (Figure 1F), transcript levels of S-endoglin were
significantly increased in lungs from 32- and 60-week-old
mice as compared with young animals (4 weeks old) (Figure
1G). To assess whether S-endoglin is expressed by ECs in
vivo, in situ hybridization experiments with human coronary
arteries were carried out (Figure 2). The antisense S-endog-
lin–specific riboprobe clearly hybridized with the endotheli-
um monolayer and with some ECs in the subendothelial zone
and tunica media that likely belong to the network of small
vessels that vascularize the large coronary artery. Some
scattered smooth muscle cells were also stained in the tunica
media, which is compatible with the expression of endoglin
protein in smooth muscle cells from human atherosclerotic
plaques.28 As a negative control, the sense S-endoglin–
specific riboprobe did not yield any signal above background
levels. The endothelial labeling of S-endoglin was reproduced
in human veins and lungs (supplemental Figure II).
Interaction of S-Endoglin With ALK5 and ALK1
The extracellular and cytoplasmic domains of L-endoglin
contribute to the physical and functional interaction with
ALK5 and ALK1.13,14 Thus, it was of interest to investigate
the behavior of S-endoglin in this context. Because both
isoforms share a common extracellular domain, we assessed
whether the S-endoglin cytoplasmic domain was able to
physically interact with both TGF- type I receptors. COS-7
cells were cotransfected with hemagglutinin (HA)-tagged
ALK5 or ALK1 plus the HA-tagged vectors TMCT-EndoL or
TMCT-EndoS, containing the transmembrane and cytoplas-
mic domains from L- or S-endoglin, respectively. We found
that antibodies against either ALK5 or ALK1 can coimmu-
noprecipitate the cytoplasmic tails from both endoglin iso-
forms (Figure 3A). Interestingly, the amount of TMCT-
EndoS or TMCT-EndoL coimmunoprecipitated with ALK5
was similar, whereas the amount of TMCT-EndoS coimmu-
noprecipitated with ALK1 was much lower than that of
TMCT-EndoL (Figure 3C). These results suggest that the
S-endoglin cytoplasmic tail interacts with ALK5 and ALK1
but shows a lower affinity for ALK1 than for ALK5. The
specificity of these interactions was confirmed by using an
HA-tagged irrelevant protein that yielded negative results. As
a control, a Western blot analysis of the total cellular extracts
is included (Figure 3B).
We next assayed the interacting ability of the full-length
isoform by cotransfecting Flag-tagged S-endoglin with HA-
tagged ALK5 or ALK1 in COS-7 cells. Antibodies against
the Flag epitope in S-endoglin were able to coimmunopre-
cipitate ALK5 with high yield (Figure 4A). By contrast, the
S-endoglin/ALK1 interaction appeared to be much weaker
(50-fold; Figure 4C). A Western blot analysis of total
cellular extracts was included to monitor the recombinant
protein expression (Figure 4B).
S-Endoglin and L-Endoglin Modulate the ALK5
and ALK1 Signaling Pathways Differently
The different behaviors of S-endoglin versus L-endoglin,
with respect to the interaction with the type I receptors,
Figure 2. In situ hybridization of S-endoglin in human coronary
artery. Sense (Control) and antisense S-endoglin cRNA probes
were uniformly labeled with digoxigenin-UTP and hybridized to
slides from human coronary artery. Riboprobes were detected
with anti-digoxigenin Fab fragments conjugated to alkaline
phosphatase, followed by incubation with the chromogenic sub-
strate. No contrast staining was performed. Black arrows show
the specific hybridization of S-endoglin to the endothelium,
whereas red arrows indicate occasional staining of smooth mus-
cle cells. Magnifications are indicated.
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suggest a specific functional role for S-endoglin in the
endothelial TGF- system. To address this issue, ECs were
transfected with S-endoglin expression vector and the effect
on the ALK5/ALK1 pathways was assessed (Figure 5). In
HMEC-1 cells, the presence of S-endoglin enhanced the
TGF-–induced activity of the ALK5/Smad3 specific re-
porter p(CAGA)12-Luc compared with control cells (Figure
5A). In the same experiment, L-endoglin overexpression led
to the inhibition of the p(CAGA)12-Luc activity in response to
TGF-, as reported.13 Next, the endothelial system GM7372-
EL, engineered to express human L-endoglin in the presence
of doxycycline,23 was used. Again, TGF-–induced activity
of the p(CAGA)12-Luc reporter was significantly increased
on S-endoglin expression (Figure 5B). By contrast,
L-endoglin expression, induced with doxycycline, not only
inhibited the basal TGF-–induced activity of the ALK5
reporter but also counteracted its S-endoglin–dependent en-
hancement. These results indicate that S-endoglin and
L-endoglin have distinct effects on the ALK5/Smad3 signal-
ing pathway. Because the extracellular domain is common to
both endoglin variants,11 we assessed whether the isoform-
specific cytoplasmic tails were responsible for their divergent
behavior. Dissection of the independent functional role of
each isoform is not easy to address in ECs because these cells
show high levels of the predominant L-endoglin. The parental
myoblast cell line L6E9 has the advantage of providing an
endoglin-free background, and stable transfectants expressing
either L-endoglin or S-endoglin19 somehow mimic the inde-
pendent contribution of each isoform in young or senescent
cells, respectively. Thus, myoblasts stably expressing
S-endoglin or L-endoglin were transfected with TMCT-
EndoL or TMCT-EndoS constructs, respectively. Ectopic
expression of the cytoplasmic region of L-endoglin markedly
reduced the TGF-–induced activity of the p(CAGA)12-Luc
reporter in S-endoglin–expressing cells (Figure 5C). Con-
versely, the cytoplasmic region of S-endoglin clearly en-
hanced the TGF-–induced activity of the same reporter in
L-endoglin–expressing cells, suggesting that the modulator
Figure 3. Interaction of
S-endoglin cytoplasmic tail
with ALK1 and ALK5. COS-7
cells were transiently
cotransfected with
HA-tagged ALK1 and ALK5
or S-endoglin (TMCT-EndoS)
or L-endoglin (TMCT-EndoL)
cytoplasmic tails. An irrele-
vant HA-tagged protein (*)
was included as a control.
Cell lysates were immuno-
precipitated (IP) with the
indicated antibodies. Immu-
noprecipitates (A) and total
cell lysates (B) were sub-
jected to SDS-PAGE under
reducing conditions, fol-
lowed by Western blot (WB)
with anti-HA or anti–-actin
antibodies. Bands corre-




and were normalized. The
mean of 3 different experi-
ments is shown in C.
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effect of endoglin isoforms on the ALK5 pathway depends on
their cytoplasmic region.
The differential effect of S-endoglin versus L-endoglin was
also assessed using the p(BRE)2-Luc reporter vector as a
sensor for the ALK1/Smad1 pathway. S-endoglin expression
did not affect the basal reporter activity, whereas the presence
of L-endoglin markedly induced the p(BRE)2-Luc activity
(Figure 5D). As expected, high doses of TGF-1 inhibited
p(BRE)2-Luc activity.
The results shown above indicate that S-endoglin and
L-endoglin isoforms have distinct functional roles on the
ALK5 and ALK1 signaling pathways. Because upregulation
of PAI-1 and Id1 is specifically dependent on the TGF-/
ALK5 or TGF-/ALK1 pathway, respectively,15,29 we as-
sessed the effect of S-endoglin on pId1-Luc and p800-Luc
reporters driven by the promoters of these genes. On trans-
fection of HMEC-1, the Id1 promoter activity, both in the
absence and in the presence of TGF-1, decreased in response
to increasing amounts of S-endoglin (Figure 5E). As a
control, L-endoglin induced the transcriptional activity of
pId1-Luc vector. On the other hand, increasing amounts of
S-endoglin augmented in a dose-dependent fashion the activ-
ity of the PAI-1 reporter (Figure 5F). By contrast, L-endoglin
inhibited the activity of PAI-1 reporter, as expected. More-
over, the effect of S-endoglin on the expression of the
senescence associated markers PAI-1 and Id1,4,30 was as-
sessed in senescent ECs whose S-endoglin levels are upregu-
lated (Figure 1). As shown by semiquantitative RT-PCR
experiments, senescent HUVECs display higher transcript
levels of PAI-1 and lower transcript levels of Id1 than control
cells (Figure 5G). In the same experiment, no significant
differences in the levels of ALK1 or ALK5 were observed.
As expected, the transcript levels of telomerase, a marker of
senescence, were clearly downregulated. To address the role
of S-endoglin in EC proliferation, murine lung ECs derived
from S-Eng transgenic animals were analyzed. As shown
in Figure 5H, S-Eng ECs displayed a lower proliferation
rate than ECs from wild-type animals. Because cellular
senescence is associated with decreased cell proliferation,
this result supports the contribution of S-endoglin to EC
senescence.
Taken together, these results suggest that, at variance with
L-endoglin, S-endoglin potentiates the ALK5 pathway, lead-
ing to increased PAI-1, whereas it inhibits the ALK1 route,
leading to decreased Id1 expression, thus mimicking the
phenotype of senescent ECs.
Hemodynamics and eNOS Expression in
Transgenic Mice Expressing S-Endoglin
The prevalence of cardiovascular disease increases with age
and is associated with increased arterial pressure and de-
creased expression and/or activity of eNOS. To address the
potential contribution of S-endoglin to the vascular pathol-
ogy, S-Eng transgenic mice25 were analyzed. The weight
was similar for S-Eng mice and control littermates (supple-
mental Figure III). Systolic, diastolic and mean arterial
pressure values were higher in S-Eng than in control
littermates (Figure 6A through 6C), whereas no significant
differences were observed in heart rate (Figure 6D). Because
endoglin regulates the expression of eNOS and thereby the
NO-dependent vascular homeostasis,20 the role of NO was
next addressed. Intravenous infusion of the nonspecific nitric
oxide synthase inhibitor NG-nitro-L-arginine methyl ester
(L-NAME) increased blood pressure in both S-Eng and
control littermate mice (Figure 6E and 6F), while reducing
the heart rate (Figure 6G). Interestingly, L-NAME infusion
resulted in a smaller increase in systolic and diastolic (33%
less) blood pressure in S-Eng as compared with control
mice (Figure 6E and 6F), suggesting less biologically
available NO in the setting of S-Eng overexpression.
Furthermore, acetylcholine-induced hypotension, an effect
that is also mediated by NO, was significantly reduced in
S-Eng as compared with control mice, whereas no signifi-
cant differences were observed with sodium nitroprusside (an
NO synthesis–independent, cGMP-dependent vasodilator) or
with hydralazine (an NO synthesis–independent, cGMP-
independent vasodilator) (supplemental Table II), again sug-
gesting a lower NO production in S-Eng as compared with
Figure 4. Interaction of full-length S-endoglin with ALK1 and
ALK5. COS-7 cells were transiently cotransfected with Flag-
tagged S-endoglin and HA-tagged ALK5 or ALK1. Cell lysates
were immunoprecipitated with anti-Flag antibodies. Immunopre-
cipitates (A) and total cellular lysates (B) were subjected to SDS-
PAGE under nonreducing conditions, followed by Western blot
analysis. -Actin was included as a loading control. Bands cor-
responding to the coimmunoprecipitated ALK1 and ALK5 were
subjected to densitometry and were normalized. The mean of 3
different experiments is shown in C.
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Figure 5. Effect of S-endoglin expression on ALK5 and ALK1 pathways. A, HMEC-1 cells were cotransfected with p(CAGA)12-Luc
reporter construct, S-endoglin (S), and L-endoglin (L). The luciferase activity in response to 10 ng/mL TGF-1 for 24 hours was mea-
sured as an indicator of the ALK5/Smad3 pathway. B, Endothelial GM7372-EL cells were cotransfected with p(CAGA)12-Luc reporter
construct and S-endoglin. Expression of L-endoglin was induced with 500 ng/mL doxycycline, and the luciferase activity in response to
TGF-1 was determined. C, L6E9 stable transfectants for S-endoglin (Endo-S) or L-endoglin (Endo-L) were transiently cotransfected
with S-endoglin (TMCT-Endo-S) or L-endoglin (TMCT-Endo-L) cytoplasmic tails, respectively, and p(CAGA)12-Luc vector. The reporter
activity in response to 10 ng/mL TGF-1 for 24 hours was determined. For clarity, the negligible reporter activity in the absence of
TGF- has been omitted. D, HMEC-1 cells were cotransfected with p(BRE)2-Luc reporter construct, S-endoglin (S), and L-endoglin (L),
as indicated. The luciferase activity was measured as an indicator of the ALK1 pathway. Significant differences were observed between
TGF-–treated and untreated cells (*P0.01). E and F, Antagonistic effect of S-endoglin on the PAI-1 and Id1 promoters. HMEC-1 cells
were transfected with pId1-Luc reporter vector containing the Id1 promoter, p800-Luc reporter vector containing the PAI-1 promoter,
and different amounts of S-endoglin or L-endoglin expression vectors. Cells were treated or not with 10 ng/mL TGF-1 for 24 hours,
and the luciferase activity was determined. Significant differences were observed between endoglin-transfected and control cells.
*P0.01, #P0.05. G, Effect of endothelial senescence on Id1 and PAI-1 expression. Total RNA was isolated from young (Y) (third
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control mice. In fact, lower urinary nitrite excretion in
S-Eng mice compared with control littermates was observed
(Figure 6H), thus reflecting a reduced renal NO synthesis. In
addition, eNOS expression was significantly lower, whereas
cyclooxygenase (COX)-2 expression was significantly
higher, in either kidney or lungs of S-Eng mice compared
with control littermates (Figure 7A and 7B). Because TGF-1
leads to an increased vasodilatation in Eng/ mice that is
severely impaired in Eng/ mice,21 the possible involvement
of S-endoglin in the TGF--regulated vascular homeostasis
was addressed next. S-Eng mice and control littermates
showed a decrease in arterial pressure (diastolic and systolic)
after TGF-1 injection, but the decrease was significantly
lower in S-Eng mice than in control littermates (Figure 7C
and 7D). As a control, no significant differences were
observed in the effects of TGF-1 on heart rate between
S-Eng mice and control littermates (Figure 7E).
Discussion
Senescence of endothelial cells plays a critical role in
cardiovascular diseases that are associated with aging. How-
ever, the underlying molecular mechanisms that involve the
senescent ECs are poorly understood. Here, we report, for the
first time, that expression of S-endoglin is induced during
senescence of ECs (Figure 8). We provide evidence that in
vivo and in vitro expression of S-endoglin contributes to the
cardiovascular pathology associated with age, although a
limitation of this study is the lack of functional analysis on
blocking S-endoglin. Our present data support that upregula-
tion of S-endoglin expression is part of the senescent program
of ECs rather than being the sole responsible for senescence.
To date, most of the studies on endoglin have focused on
the predominant L-endoglin isoform, although significant
levels of S-endoglin mRNA are coexpressed with L-endoglin
in vivo.11,12 These isoforms are generated by alternative
splicing, and the only difference between human S-endoglin
and L-endoglin transcripts is an intronic sequence of 135-bp
that is retained in S-endoglin.11 Unfortunately, no consensus
small interfering RNA motifs could be identified in this
sequence. Consequently, the analysis of functional effects of
S-endoglin silencing is not feasible, and this represents a
technical limitation of this study. On the other hand,
passage) or senescent (S) (13th passage) HUVECs as in Figure 1. Samples were subjected to RT-PCR using specific primers (supplemen-
tal Table I) for Id1, PAI-1, ALK1, ALK5, human telomerase reverse transcriptase (hTERT), and GAPDH as an internal control. Transcript levels
were normalized with respect to GAPDH, giving an arbitrary value of 10 (Id1, hTERT) or 1 (PAI-1, ALK1, ALK5) to young HUVECs. Densitome-
try of 3 different experiments was carried out, and the meansSEM is shown. H, Effect of S-endoglin expression on cellular proliferation.
Pools from primary lung ECs from 3 S-Eng or 3 wild-type (WT) mice were plated, and, at the times indicated, proliferation was assessed
using an MTT assay by measuring the optical density at 570 nm. Each data point is the mean of triplicate samples. This is a representative
experiment out of 4 different experiments using MTT or crystal violet staining.
Figure 6. Arterial pressure in S-Eng mice. A through D, Systolic (A), diastolic (B), and mean arterial (C) pressures were measured by
radiotelemetry in S-Eng and control mice. The heart rate was also measured (D). E through G, Effect of NO synthesis inhibition. Varia-
tion of systolic pressure (E), diastolic pressure (F), and heart rate (G) were measured in S-Eng and control mice intraperitoneally
infused or not with L-NAME. Arbitrary values of 100 were assigned to untreated animals. H, NO synthesis. Concentration of nitrites in
urine was determined. Significant differences were observed between S-Eng and control mice (*P0.01).
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S-endoglin and L-endoglin proteins vary from each other in
their cytoplasmic tails that contain 14 and 47 amino acids,
respectively, with a sequence of only 7 residues being
specific for S-endoglin. This small structural difference
explains the lack of appropriate tools to clearly distinguish
between L-endoglin and S-endoglin in tissues and primary
cultured cells. Thus, analysis by ectopic expression of cDNAs
encoding human L- and S-endoglin in cell transfectants and
transgenic mice represents an excellent model system to
understand the role of these isoforms. In this study, we
demonstrate that the functional role of L-endoglin is different
from that of S-endoglin in ECs. This comparative study has
been addressed by analyzing the TGF- signaling pathway in
ECs, where the TGF- type I receptors ALK1 and ALK5
appear to play an active role in regulating the activation/
resolution phases of angiogenesis.8,15 We show that
S-endoglin interacts with both ALK5 and ALK1, although the
interaction with ALK5 was stronger than with ALK1. This is
at variance with L-endoglin that shows a higher affinity for
ALK1 versus ALK5.13 Because the extracellular domain of
endoglin is common in both isoforms, their cytoplasmic tails
appear to be responsible for these differences. Thus, whereas
ALK5 interacts with both endoglin cytoplasmic tails with
comparable affinity, the interaction between ALK1 and the
cytoplasmic tail of S-endoglin was significantly lower than
with the long counterpart. Moreover, S-endoglin behaved
differently than L-endoglin in relation to several TGF--
responsive reporters with different specificities. Thus,
S-endoglin expression increases the ALK5 signaling path-
way, whereas L-endoglin inhibits the same pathway in ECs.
Figure 7. Endoglin-dependent vascular homeostasis in S-Eng mice. A and B, Expression of eNOS and COX-2 in lungs (A) and kid-
neys (B), as determined by Western blot. Significant differences were observed between S-Eng and wild-type mice (*P0.01). C
through E, Effect of TGF-. Variation of systolic pressure (C), diastolic pressure (D), and heart rate (E) were measured in mice infused or
not with TGF-1. Arbitrary values of 100 were assigned to untreated animals. *Significant differences (P0.01) with respect to wild-type
animals.
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Interestingly, S-endoglin also favors ALK5/Smad3 signaling
in mouse carcinoma cells and rat myoblasts.22,24 On the other
hand, L-endoglin, but not S-endoglin, stimulated the ALK1
signaling pathway. These results are in agreement with
reports showing that L-endoglin promotes endothelial cell
proliferation via TGF-/ALK1 signaling, whereas it inter-
feres with the TGF-/ALK5 pathway,9,13,15 and suggest that
S-endoglin acts as an antagonist of L-endoglin. In fact,
S-endoglin appears to have a negative effect on EC prolifer-
ation. This is compatible with the reported antiangiogenic
effect of S-endoglin in contrast to the proangiogenic role
attributed to L-endoglin.12,26,31 Interestingly, angiogenic func-
tion is progressively impaired with increasing age,32 which
fits well with the upregulation of S-endoglin in senescent ECs
and its antiangiogenic effect. This short endoglin isoform is
able to exert opposite effects to that of the predominantly
expressed L-endoglin on the TGF- signal, including the
positive and negative cooperation with ALK5 and ALK1,
respectively. Because both endoglin isoforms are coexpressed
in senescent ECs, this raises the question about the molecular
mechanism by which L-endoglin and S-endoglin antagonize
with each other. The reported heterodimeric association
between S-endoglin and L-endoglin12 could possibly account
for a mutually interfering effect. Of note, ALK5 and ALK1
levels are not significantly altered between young and senes-
cent ECs. This suggests that the S-endoglin/L-endoglin ratio
in ECs may contribute to balancing the TGF- signal through
ALK5 or ALK1 and their important roles in vascular patho-
physiology.8 In this context, increased synthesis of extracel-
lular matrix is a pathological process widely related to high
circulating levels of TGF- and with the activation of the
ALK5/Smad3 signaling pathway.33,34 Whereas S-endoglin
highly increased the ALK5 signaling pathway, L-endoglin
inhibited the same route, in agreement with a number of
reports describing the role of L-endoglin as an antagonist of
ALK5-mediated TGF- induction of extracellular matrix
synthesis.18,19,35 The positive contribution of S-endoglin to
the profibrotic TGF-/ALK5 pathway suggests its involve-
ment in the increased fibrosis associated with vascular
senescence.36
Further support for the involvement of S-endoglin in the
cardiovascular pathology associated with senescence was
obtained using S-endoglin transgenic animals. S-Eng mice
show hypertension, a defective hypertensive response to the
inhibition of NO synthesis with L-NAME, and a decreased
urinary nitrite excretion, thus suggesting a defective NO
synthesis. This interpretation is supported by the decreased
eNOS expression in lungs and kidneys of these animals, as
well as the positive relationship between levels of L-endoglin
and eNOS reported in both mice and cultured ECs.20,26 In
addition, endoglin-deficient mice show a defective endothe-
lium-dependent vasorelaxation and decreased NO produc-
tion,20 similarly to S-endoglin transgenic mice. Of note, NO
inhibits EC senescence,37 thus supporting the involvement of
S-endoglin in this process. Furthermore, in both cultured ECs
and endoglin-deficient mice, low levels of L-endoglin are
associated with high COX-2 expression,26 a correlation also
found in S-Eng mice. Thus, in vivo overexpression of
S-endoglin appears to result in the same phenotype as
L-endoglin deficiency, suggesting opposing functional effects
of both isoforms on the NO and COX-2 systems. On the other
hand, S-Eng transgenic mice also show a reduced hypoten-
sive response to TGF-1 administration, in agreement with
the finding that TGF-1 regulates eNOS expression38 and
induces vasodilatation in wild-type mice, which is severely
impaired in endoglin-deficient animals.21 Thus, S-endoglin
seems to have the opposite behavior than L-endoglin in these
vascular parameters.
Taken together, these findings suggest that the alternatively
spliced S-endoglin contributes to the cardiovascular pathol-
ogy associated with aging. Further studies on the triggering
mechanisms that control the alternative splicing of endoglin
gene will help to better understand the genetic and physio-
logical programs under which S-endoglin exert its function.
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Figure 8. Hypothetical model of S-endoglin functions during
senescence. In the normal state, the TGF- response is modu-
lated by L-endoglin, but, on senescence of ECs, S-endoglin is
upregulated, interacting with the TGF- receptor complex con-
taining ALK1 and ALK5. As a consequence of this interaction,
S-endoglin regulates the expression of different TGF- target
genes including PAI-1, Id1, eNOS, and COX-2. Thus, S-endoglin
allows a switch that triggers the cardiovascular pathology: (1)
upregulation of PAI-1/extracellular matrix (ECM) synthesis may
lead to increased fibrosis; (2) downregulation of Id1 is associ-
ated with decreased angiogenesis; and (3) downregulation of
eNOS and upregulation of COX-2 are involved in hypertension.
The involvement of TRII, TGF-, and S-endoglin/L-endoglin
heterodimers has been omitted for simplification.
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EXPANDED MATERIALS AND METHODS 
 
Cell culture 
The green monkey kidney fibroblast-like cell line COS-7 and the tetracycline-inducible bovine 
endothelial cell line GM7372-EL were cultured in DMEM and α-MEM media (Gibco, Scotland, 
UK), respectively1,2. The L-Endoglin and S-Endoglin stable transfectants of the rat skeletal 
myoblast L6E9 cell line were obtained and maintained as described3. Culture media were 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mmol/L L-glutamine, and 
100 U/mL penicillin/streptomycin. For induction of human L-Endoglin expression in GM7372-
EL cells, different concentrations (20–500 ng/mL) of doxycycline (Dox; Sigma, St. Louis, MO) 
were used in the culture media. The human microvascular endothelial cell line HMEC-14 and 
primary cultures of human umbilical vein endothelial cells (HUVECs) were maintained in 
EBM-2 plus EGM-2 SingleQuots (Cambrex, Walkersville, MD). These cells were seeded and 
grown on plates pre-coated with 0.2% gelatin type B from bovine skin (Sigma, St. Louis, MO) 
in PBS. Cells were maintained in a NAPCO incubator at 37ºC in a humidified atmosphere with 
5% CO2. When required, cells were incubated with TGF-β1 (R&D Systems, Abingdon, UK). 
Primary lung endothelial-cell isolation 
Lungs from S-Eng+ transgenic mice or normal littermates S-Eng- were minced, collagenase-
digested (Gibco Invitrogen), sieved through a 70 µm-pore size cell strainer (BD Falcon), and the 
cell suspension was seeded on plates precoated with 0.1% gelatin (Sigma), 10 µg/mL fibronectin 
(Sigma), and 30 µg/mL Vitrogen (BD Biosciences) in PBS. Endothelial cells were purified by a 
single negative (FCγ-RII/III antibody; BD Pharmingen) and two positive (ICAM-2; BD 
Pharmingen) cell sorts using anti-rat IgG-conjugated magnetic beads (Dynal, Invitrogen). Cells 
were cultured routinely in a 50:50 mixture of Ham’s F-12:DMEM media supplemented with 
20% FCS, endothelial cell mitogen (Sigma), heparin (Sigma), and antibiotics in plates precoated 
as described above. 
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Proliferation Assays 
Primary mouse lung endothelial cells were seeded onto precoated 96-well culture plates at 1,000 
cells/well, and proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium (MTT; Roche) over 6 days. The MTT metabolic product (formazan) was 
resuspended in DMSO and the optical density was measured at 570 nm. Samples were also 
analyzed by crystal violet staining. Cells were fixed in paraformaldeyde at defined time points 
and subsequently stained with crystal violet. After cell lysis with acetic acid 10%, optical 
density was measured at 595 nm. 
Senescence Associated β-Galactosidase Activity Staining 
HUVECs were cultured in 60 mm diameter gelatin pre-coated dishes. The senescence associated 
β-galactosidase (SA-β-gal) activity staining was performed as reported5. Briefly, at the indicated 
passage (from 2nd to 14th), cells were washed twice with PBS and fixed with 3.5% formaldehyde 
solution (Merck, Germany) in PBS for 5 minutes at room temperature. Next, dishes were 
washed twice and incubated at 37ºC in the absence of CO2 during 16 hours with fresh staining 
solution containing 1 mg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 40 
mmol/L citric acid/Na2HPO4 buffer (pH 6.0), 5 mmol/L K4Fe(CN)6, 5 mmol/L K3Fe(CN)6, 2 
mmol/L MgCl2 and 150 mmol/L NaCl. The stained cells were observed with a phase contrast 
Axiovert 25 inverted microscope (Zeiss, Germany). The SA-β-gal activity was revealed as a 
blue coloured cytoplasm and the number of cells with SA-β-gal activity was determined as a 
mean of four random fields. 
RT-PCR 
For semiquantitative RT-PCR, total RNA from HUVECs was obtained using the TRIzol 
Reagent (Invitrogen, Scotland, UK) according to the manufacturer’s instructions. The isolated 
RNA was resuspended in TE buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0). Then, 
cDNA synthesis from 1 μg of total RNA was performed in 20 μL with the First Strand cDNA 
Synthesis kit for RT-PCR (AMV; Roche Diagnostic, Germany) using an oligo(dT)15 primer, 
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following the commercial recommendations. Five μL of fresh cDNA was subjected to PCR 
amplification using the HotMaster Taq DNA Polymerase kit (Eppendorf, Germany). PCR 
products were resolved by agarose gel electrophoresis. Transcripts of human Endoglin ALK1, 
ALK5, TβRII, telomerase reverse transcriptase (hTERT) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), as control, were amplified using specific primers (Online Table I). S-
Endoglin was detected as a 285-bp band, whereas L-Endoglin was identified as a 150-bp band6. 
Gels were documented in a Gel Doc XR System (Bio-Rad, Hercules, CA) and bands were 
quantified using the Quantity One software. 
For quantitative RT-PCR, mouse tissue RNA was obtained using Tripure reagent (Roche, 
Mannheim, Germany). The determination of the transcript levels was performed by 
quantification assays on the basis of real-time RT-PCR with a LightCycler instrument (Roche 
Diagnostic, Penzberg, Germany) using fluorescence resonance energy-transfer (FRET) 
hybridization methodology. The gene encoding the 18S RNA was used as an internal control of 
the RNA quality and amplification. Primers used to amplify mouse Endoglin7 or 18S RNAs are 
indicated in online Table I. The hybridization probes were designed by TibMolBiol (Berlin, 
Germany). Reactions for real-time PCR were performed using the one-step LightCycler kit 
(Roche). Four hundred ng of total cellular RNA from each tissue sample were used to generate 
cDNA in a reaction containing 3.25 mmol/L of Mn(OAc)2, 0.5 μmol/L of each primer, 0.2 
μmol/L of each probe and 1 x LC RNA Master Hybridization Probes mix (Roche). The cDNAs 
of Endoglin and 18S were subsequently co-amplified using the following PCR conditions: 95ºC 
for 2 min followed by 40 cycles with 95ºC for 10 s, 55ºC for 30 s and 72ºC for 15s. All PCR 
reactions were repeated for each sample in three independent experiments. Endoglin expression 
levels were calculated with the LightCycler Relative Quantification software (Roche). 
In situ hybridization 
To detect human S-Endoglin specific mRNA,6 the intronic sequence of ENG gene flanked by 
part of exons #13 and #14 was amplified by PCR using the primers pair 5’-
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CTCATCGGGGCCCTGCTC-3’ and 5’-TGCTGCTCTCCGAGGAGG-3’, and cloned using the 
TA Cloning kit Dual Promoter (Invitrogen). Sense control and antisense S-Endoglin cRNA 
probes (of ~250 nt) were uniformly labeled with digoxigenin-UTP using DIG RNA Labeling Kit 
Sp6/T7 (Roche), precipitated, and resuspended in hybridization buffer (50% deionized 
formamide, 2% Blocking Reagent from Roche, 5x SSC, 1 mg/ml total yeast tRNA, 0.1% 
Tween-20, 0.1% CHAPS, and 5 mM EDTA pH 8). Paraffin embedded slides from human 
coronary artery, vein, and lungs were purchased from Gentaur (Brussels, Belgium). Slides were 
deparaffinized in xylene, rehydrated, and postfixed. The sections were digested with proteinase 
K, treated with 2% glycine, washed and hybridized overnight at 65°C. Next, slides were washed 
at 65°C in 50% formamide, 2x SSC, and then at room temperature in PBST (PBS, 0.1% Tween-
20). Slides were incubated with blocking buffer (2% Blocking Reagent from Roche, and 10% 
heat inactivated fetal calf serum in PBST) for 1 hour at room temperature. Hybridized 
riboprobes were detected with anti-digoxigenin Fab fragments conjugated with alkaline 
phosphatase (Roche) and the specific signal was revealed with a mixture of nitroblue 
tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt (NBT/BCIP 
solution, Roche), according to the manufacturer’s instructions. Slides were visualized and 
photographed using an Axiovert 25 inverted microscope (Zeiss, Germany). 
Expression Vectors and Transfections 
Expression vectors encoding the HA-tagged truncated versions of human Endoglin TMCT-
Endo-L and TMCT-Endo-S in pDisplay (Invitrogen) were generated as described8. TMCT-
Endo-L and TMCT-Endo-S contain the transmembrane and cytoplasmic domains of L- and S-
Endoglin, respectively. The expression vector pcDNA3-Endo-S encoding the Flag-tagged full-
length human Endoglin-S has been reported9. HA-tagged expression vector encoding wild type 
ALK1 in pcDNA3-HASL plasmid was provided by Dr. K. Miyazono (University of Tokyo, 
Japan). The HA-tagged wild type ALK5 in pCMV5 was supplied by Dr. L. Attisano (University 
of Toronto, Canada). 
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Cell transfections were carried out with SuperFect Reagent (Qiagen), according to the 
manufacturer’s instructions. Alternatively, a household cationic liposome containing 3 beta 
[N(N',N-dimethylaminoethane) carbamoyl] cholesterol (DC-chol) and 
dioleoylphosphatidylethanolamine (DOPE) (Sigma) was used. Briefly, a 20x concentrated stock 
solution of DC-chol:DOPE was prepared dissolving 10μl of each one in 1 mL of 37ºC warmed 
ethanol. The mixture was homogenized with the help of a 25G syringe and then incubated for 10 
minutes at 37ºC. The working solution was prepared immediately before transfection in sterile 
water and filtered through 0.2 μm (Sartorius). The DNA (μg):reagent (μL) ratio was optimized 
to 1:5 for all experiments. 
Reporter Assays 
Reporter assays with TGF-β-responsive promoter constructs were performed by transient 
transfection as described1, using the ALK5/Smad3 specific p(CAGA)12-Luc10, the 
ALK1/Smad1/5/8 specific p(BRE)2-Luc11, p800-Luc, containing the PAI-1 promoter12 and pId1-
Luc, containing the Id1 promoter13 vectors in the presence or absence of TGF-β1. Relative 
luciferase units were determined in a TD20/20 luminometer (Promega, Madison, WI). Samples 
were co-transfected with the SV40-β-galactosidase expression plasmid as an internal control to 
correct for transfection efficiency. Measurement of β-galactosidase activity was performed using 
the Galacto-Ligth kit (Tropix). The experiments were performed in triplicate at least three times 
and representative experiments are shown in the figures. 
Immunoprecipitation and Western-blot analyses 
Transfected cells were lysed at 4ºC for 30 minutes with lysis buffer (50 mmol/L pH 7.4 HEPES, 
150 mmol/L NaCl, 100 μmol/L EGTA, 500 μmol/L EDTA, 10 mmol/L NaF, 1 mmol/L 
Na3VO4, 10% digitonin, 10% glycerol and a mixture of protease inhibitors (Complete, Roche). 
Aliquots of total cell lysates were subjected to SDS-PAGE and electrotransferred to a PVDF 
membrane for specific immunodetection. For immunoprecipitation studies, aliquots of total cell 
lysates containing equal amounts of total protein were pre-cleared for 4 hours with protein G 
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coupled to Sepharose (Amersham Biosciences) at 4ºC. Specific immunoprecipitations of the 
pre-cleared lysates were carried out in the presence of the appropriate antibody, coupled to 
protein G-Sepharose. After overnight incubation at 4ºC, immunoprecipitates were isolated by 
centrifugation and washed three times with lysis buffer. Precipitated proteins were separated by 
SDS-PAGE, electrotransferred to a PVDF membrane and immunodetected. Specific protein 
bands were revealed with the SuperSignal chemiluminescent substrate (Pierce). 
Animals and Housing 
Mice from the strain C57BL/6J of different ages (4, 32 and 60 weeks old), were obtained from 
The Jackson Laboratory (Bar Harbor, ME, USA). Their lungs were excised and snap frozen in 
liquid nitrogen for quantitative RT-PCR studies. Transgenic mice expressing human S-Endoglin 
under the control of the endothelial-specific promoter ICAM-2 (S-Eng+ mice) have been 
previously described14. Briefly, transgenic mice were obtained by microinjection of the pICAM-
2/S-Eng construct into fertilized C57Bl/6xSJL mouse embryos, and backcrossed at least five 
times with C57Bl/6 mice. Transgenic S-Eng+ animals were genotyped using two sets of primers 
amplifying a 300-bp product for the endogenous mouse endoglin, and a 604-bp product for the 
transgene, as previously described9. Experiments were performed in parallel on S-Eng+ mice and 
littermates that did not carry the transgene weighing 25-30 g at the time of radiotelemetry 
implant. Multiple simultaneous measurements were made with each mouse as indicated. 
All procedures were approved by the Animal Care and Use Committees of the University of 
Salamanca and Instituto de Investigaciones Biomédicas Alberto Sols, and mice were cared for in 
accordance with the standards established in the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. 
Direct Measurement of Blood Pressure: Radiotelemetry Methods 
Arterial pressure was measured by telemetry in animals without anaesthesia or movement 
restriction, thus avoiding the confounding effects of anaesthesia and movement restriction on 
arterial pressure. Radiotelemetry system blood pressure measurement is performed through a 
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catheter implanted into an artery of the mouse. The catheter is attached to a combination 
pressure transducer, transmitter, and battery, all encapsulated in an implantable 
microminiaturized electronic monitor (PA-C20, Data Sciences International, DSI; St. Paul, 
MN). For device implantation in the mice, we have used the technique described by Whitesall et 
al. (2004)15. In brief, after anesthesia (Ketamin 78 mg·Kg-1, Diazepam 6 mg·Kg-1, and Atropine 
0,15 mg·Kg-1; i.p.) a two skin incision were made, one 20-30 mm long from pelvis to xiphoid 
process and other in the neck from chin to manubrium. Then, a subcutaneous channel from the 
neck site to the abdominal site was made by blunt dissection and a 16-gauge trocar was passed 
from the abdominal to the neck incision. The catheter of the implant was passed into the trocar, 
and the implant body was inserted in the abdominal cavity through a midline incision made in 
the abdominal muscles and secured with six to eight interrupted nonabsorbable sutures (4-0 
braided polyester). The muscle was closed with continuous sutures, the skin was closed with 
staples, and topical antiseptic was applied. Next, carotid artery was cannulated with the device’s 
catheter and the skin was closed. Then, approximately 1 mL of normal saline was injected 
subcutaneously and the animal was kept in a warmed environment for at least 24 h to allow the 
recovering from surgery. An analgesic (buprenorphine, 0.1 mg·Kg-1 i.m., Buprex, Schering-
Plough, Madrid, Spain) was provided if the animal behavior suggested the presence of pain. An 
antibiotic (cefazolin 25mg·Kg-1, Normon, Spain) was administered at the time of the operation 
and twice daily during recovery. Each animal was housed individually in a standard 
polypropylene cage in a 12:12-h light-dark cycle, fed standard rodent chow, and given drinking 
water ad libitum. At least 3 days after recovery, the cage was placed over a radio receiver in a 
quiet environment, and repeated measurements of basal systolic and diastolic arterial pressure 
and heart rate were performed in each animal between 10:00 and 14:00 a.m., for at least 3 days. 
Responses of arterial pressure to intraperitoneal administration of L-NAME (50 mg·kg-1), 
acetylcholine (1μg·kg-1), hydralazine (0.2 mg·kg-1), nitroprusside (2 mg·kg-1) or TGF-β1 (5 
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μg.kg-1) were also recorded in a similar way as basal data. Data was digitally recorder on a 
computer and processed using the software provided by Data Sciences. 
When pressure measurement was finished, animals were anesthetized with a mixture of 
ketamine (100 mg·kg-1) and xylazine (5 mg·kg-1), the implant was removed and lungs and 
kidneys were immediately frozen in liquid nitrogen. 
Biochemical measurements 
For urinary nitrite measurements, mice were placed in metabolic cages and urine was collected 
free of food and faeces. Urinary nitrite concentration was measured using the Griess reactive, as 
previously described16. eNOS and COX-2 expression in extracts from kidneys and lungs was 
assessed as previously described16. Antibodies used were anti-eNOS (sc-654) and anti-COX-2 
(sc-1745) both from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Statistics 
All data are given as means ±SEM from at least three independent experiments. Statistical 
significance was evaluated using the Students’ t-test. Differences were considered to be 
significant at a value of P<0.05. 
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Reverse                       Forward
Specific Primers used for RT-PCR
Sequence (5’? 3’)
Target
Online Table I. Nucleotide sequences of specific primers used to amplify L-Endoglin, S-Endoglin, ALK1, ALK5, TβR-II, human 
telomerase reverse transcriptase (hTERT), Id1, PAI-1, 18S RNA and GAPDH transcripts by PCR. Human Endoglin cytoplasmic
(Endoglin-CT) primers #1 simultaneously detect the cytoplasmic (CT) regions of L-Endoglin (150-bp) and S-Endoglin (285-pb) 
isoforms. Mouse endoglin primers #6 detect the S-Endoglin isoform.
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 Absolute values (mmHg) 





        
None Systolic pressure Eng+ (83) 135 ± 2    
  WT (75) 108 ± 2*    
        
 Diastolic pressure Eng+ (83) 105 ± 2    
  WT (75) 87 ± 2*    
        
Acetilcholine Systolic pressure Eng+ (20) 131 ± 3 122 ± 3 -9 ± 2 -6.8 ± 0.2 
(1 μg·kg-1)  WT (15) 105 ± 3* 95 ± 5* -10 ± 2 -9.5 ± 0.3* 
        
 Diastolic pressure Eng+ (20) 112 ± 2 104 ± 4 -8 ± 2 -7.1 ± 0.3 
  WT (15) 87 ± 3* 75 ± 5* -12 ± 2 -13.7 ± 0.3* 
        
L-NAME Systolic pressure Eng+ (30) 137 ± 3 151 ± 3 23 ± 2 16.7 ± 0.78 
(50 mg·kg-1)  WT (22) 107 ± 4* 141 ± 5 34 ± 2* 31.2 ± 0.9* 
        
 Diastolic pressure Eng+ (30) 108 ± 3 127 ± 3 19 ± 2 17.5 ± 0.7 
  WT (22) 83 ± 4* 116 ± 4 33 ± 2 38.3 ± 1.0* 
        
Hydralazine Systolic pressure Eng+ (10) 144 ± 4 110 ± 5 -34 ± 4 -23.6 ± 2.7 
(0.2 mg·kg-1)  WT (10) 113 ± 6* 78 ± 6* -35 ± 4 -30.7 ± 3.9 
        
 Diastolic pressure Eng+ (10) 117 ± 4 91 ± 3 -26± 2 -22.2 ± 2.7 
  WT (10) 87 ± 6* 57 ± 4* -30 ± 4 -34.4 ± 3.4* 
        
Nitroprusside Systolic pressure Eng+ (23) 135 ± 3 77 ± 3 -58 ± 7 -42.9 ± 4.7 
(2 mg·kg-1)  WT (18) 113 ± 5* 78 ± 4 -55 ± 6 -51.7 ± 5.9 
        
 Diastolic pressure Eng+ (23) 105 ± 2 55 ± 6 -50 ± 2 -47.6 ± 5.7 
  WT (18) 88 ± 4* 37 ± 5* -52 ± 4 -59.0 ± 3.4* 
        
TGF-β1 Systolic pressure Eng+ (10) 131 ± 3 122 ± 12 -9 ± 2 -  6.8 ± 0.2 
(5 μg·kg-1)  WT (10) 105 ± 4* 88 ± 19* -17 ± 2* -10.5 ± 0.4* 
        
 Diastolic pressure Eng+ (10) 106 ± 3 99 ± 6 -7 ± 2 -  6.6 ± 0.4 
  WT (10) 88 ± 5* 73 ± 5* -15 ± 2* -17.5 ± 0.7* 
 
Online Table II. Hemodynamic values in transgenic mice expressing S-Endoglin (*P<0.01). 
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Online Figure I. Cell size analysis of SA-β-gal positive endothelial cells. HUVECs were seeded onto gelatin coated plates 
and passages were performed when cells achieved ~90% confluence. At passages 12-14, cells were stained for SA-β-gal 
activity. Blue cytoplasmic staining in cells positive for SA-β-gal was considered as a marker for senescent cells. The 
percentage that the nuclear area represents respect to the whole cell was measured in senescent and non-senescent cells 
from at least  four random fields and was represented as the mean ±SD (panel A). The nuclear area (in pixels) of senescent 
and non-senescent cells was measured in at least  four random fields and represented as the mean ±SD (panel B). This is a 
representative experiment out of three different ones. The surface ratio Nucleus/Cell is significantly much lower in  senescent 
versus non-senescent cells (*p<2.37x10-9). As a control, no significant differences (NS) were observed in the nuclear area 
between senescent and non-senescent cells. 
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Online Figure II. In situ hybridization of S-Endoglin in human veins and lung. Sense 
(Control) and antisense S-Endoglin cRNA probes were uniformly labeled with 
digoxigenin-UTP and hybridized to slides from human coronary artery. Riboprobes were 
detected with anti-digoxigenin Fab fragments conjugated to alkaline phosphatase, 
followed by incubation with the chromogenic substrate. No contrast staining was 
performed. Slides were photographed at the indicated magnifications. Black arrows 
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